Remicade Sales Data
| Rank 8 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Remicade U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 8 | $994,020 | -2.71% | 1,568 | -4.85% |
| Q3 2013 | 8 | $1,021,678 | 2.60% | 1,648 | 2.42% |
| Q2 2013 | 8 | $995,800 | 2.76% | 1,609 | 1.19% |
| Q1 2013 | 8 | $969,058 | 3.58% | 1,590 | 2.51% |
| Q4 2012 | 8 | $935,584 | -1.73% | 1,551 | -4.32% |
| Q3 2012 | 8 ( 2) |
$952,068 | 2.02% | 1,621 | 1.76% |
| Q2 2012 | 10 (1) |
$933,255 | 3.76% | 1,593 | 2.38% |
| Q1 2012 | 11 (2) |
$899,453 | 10.04% | 1,556 | 10.04% |
| Q4 2011 | 13 ( 3) |
$817,365 | -7.02% | 1,414 | -9.82% |
| Q3 2011 | 10 | $879,054 | 1.52% | 1,568 | 1.03% |
| Q2 2011 | 10 (2) |
$865,903 | 7.61% | 1,552 | 7.11% |
| Q1 2011 | 12 | $804,699 | n/a | 1,449 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
